Published summary: 2026-03-07
Where the evidence converges
Meta-analysis of 20 fMRI studies found cannabis users show altered brain activation patterns, with different changes in adults (temporal/frontal regions) versus adolescents (parietal/putamen)
Strong evidence · 13 studies
The studies included used different cognitive tasks, which complicates interpretation of pooled results. The meta-analysis cannot determine whether brain changes preceded or followed cannabis use. Cro
Neuroimaging meta-analysis found cannabis users consistently show decreased activation in cognitive control regions (ACC, DLPFC) and increased activation in reward regions (striatum)
Strong evidence · 13 studies
Cross-sectional neuroimaging studies cannot determine whether brain changes preceded or followed cannabis use. Heterogeneity in cannabis use patterns across studies. Meta-analytic approach may miss su
Meta-analysis of 30 neuroimaging studies found regular cannabis users have significantly smaller hippocampus and orbitofrontal cortex volumes
Strong evidence · 13 studies
Cross-sectional studies cannot determine whether smaller volumes preceded or resulted from cannabis use. Significant heterogeneity in hippocampal results (I2=74%). No significant dose-response relatio
Where questions remain
A 1983 review found THC outperformed placebo and standard drugs for chemotherapy nausea, with effectiveness linked to the "high
Moderate evidence · 150 studies
Narrative review format means no systematic quality assessment of included studies. The correlation between "high" and efficacy could reflect unblinding rather than a true mechanistic link.
CBD at approximately 700 mg/day for six weeks showed no significant benefit for Huntington's Disease symptoms in 15 patients, but was well tolerated with no toxicity
Moderate evidence · 150 studies
Fifteen patients is a small sample. Six weeks may be too short to detect slowly developing benefits. The crossover design assumes no carryover effects. Plasma CBD levels were relatively low despite hi
Animal studies showed chronic THC altered the hippocampus in rats, but required at least 3 months of exposure in young animals
Moderate evidence · 150 studies
Animal models have inherent limitations for predicting human neurotoxicity. Dose scaling between species is imprecise. The review predated the discovery of cannabinoid receptors in the hippocampus, so
A 1992 review found that despite widespread human use, animals would not self-administer THC and evidence of brain reward pathway stimulation was minimal
Moderate evidence · 150 studies
Published at the very beginning of the cannabinoid receptor era. Many of the puzzles identified were later resolved by endocannabinoid system research. The review's characterization of limited reward
Research gaps
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Adolescent Cannabinoid Exposure Produced Schizophrenia-Like Behavior Across 359 Animal Experiments
This is the first meta-analysis to comprehensively test whether epidemiological links between adolescent cannabis use and schizophrenia are supported by controlled animal experiments. The consistent findings across hundreds of experiments strengthen the biological plausibility of this association.
Where THC acts in the brain depends on dose and how many cannabinoid receptors are present
Identifying where THC acts most strongly in the brain, and why, helps explain the wide range of cognitive effects reported by cannabis users and could inform dosing strategies for therapeutic applications.
Large meta-analysis maps how youth cannabis use changes brain activation patterns
Understanding how cannabis changes brain function in young people is critical because the adolescent brain is still developing. This meta-analysis provides the most comprehensive picture to date of where those changes occur.
Mega-analysis of 400 THC infusions confirms THC induces psychosis-like symptoms in nearly half of healthy volunteers
This is the most comprehensive analysis of THC-induced psychosis-like effects in controlled settings, confirming the dose-dependent relationship and demonstrating that tolerance from regular use partially protects against these effects.
Meta-analysis confirms a single dose of THC induces psychotic, negative, and other psychiatric symptoms with large effect sizes
This is the most comprehensive meta-analysis of controlled THC administration studies, providing definitive effect size estimates for THC-induced psychiatric symptoms and finding no consistent evidence that CBD protects against these effects.
Meta-analysis confirms regular cannabis users have smaller hippocampus and orbitofrontal cortex
This is the most comprehensive neuroimaging meta-analysis on cannabis to date, providing quantitative evidence that regular use is associated with structural brain differences in regions that underpin the cognitive deficits commonly reported.
How the research developed
Pre-2000
25 studies published. Includes 1 RCTs, 2 strong-evidence studies.
2000–2009
120 studies published. Includes 5 RCTs, 6 strong-evidence studies.
2010–2014
181 studies published. Includes 15 RCTs, 1 strong-evidence studies.
2015–2019
372 studies published. Includes 5 meta-analyses, 23 RCTs, 25 strong-evidence studies.
2020–present
618 studies published. Includes 11 meta-analyses, 26 RCTs, 39 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 1316 peer-reviewed studies: 16 meta-analyses (1%), 70 randomized controlled trials (5%), 194 observational studies (15%), 313 reviews (24%), 16 case studies (1%), 707 other study types (54%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.